These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 35731023)
1. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023 [TBL] [Abstract][Full Text] [Related]
2. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622 [TBL] [Abstract][Full Text] [Related]
3. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature. Tong A; Li M; Cui Y; Ma X; Wang H; Li Y Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978 [No Abstract] [Full Text] [Related]
4. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741 [TBL] [Abstract][Full Text] [Related]
6. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. Xekouki P; Szarek E; Bullova P; Giubellino A; Quezado M; Mastroyannis SA; Mastorakos P; Wassif CA; Raygada M; Rentia N; Dye L; Cougnoux A; Koziol D; Sierra Mde L; Lyssikatos C; Belyavskaya E; Malchoff C; Moline J; Eng C; Maher LJ; Pacak K; Lodish M; Stratakis CA J Clin Endocrinol Metab; 2015 May; 100(5):E710-9. PubMed ID: 25695889 [TBL] [Abstract][Full Text] [Related]
7. Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome. Patócs A; Lendvai NK; Butz H; Liko I; Sapi Z; Szucs N; Toth G; Grolmusz VK; Igaz P; Toth M; Rácz K Pathol Oncol Res; 2016 Oct; 22(4):673-9. PubMed ID: 26960314 [TBL] [Abstract][Full Text] [Related]
8. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma. Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498 [TBL] [Abstract][Full Text] [Related]
9. GROWTH RATE OF PARAGANGLIOMAS RELATED TO GERMLINE MUTATIONS OF THE SDHX GENES. Michałowska I; Ćwikła JB; Michalski W; Wyrwicz LS; Prejbisz A; Szperl M; Nieć D; Neumann HP; Januszewicz A; Pęczkowska M Endocr Pract; 2017 Mar; 23(3):342-352. PubMed ID: 27967220 [TBL] [Abstract][Full Text] [Related]
10. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Vicha A; Musil Z; Pacak K Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):186-91. PubMed ID: 23481210 [TBL] [Abstract][Full Text] [Related]
11. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit. Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172 [TBL] [Abstract][Full Text] [Related]
12. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions. Gabriel S; Blanchet EM; Sebag F; Chen CC; Fakhry N; Deveze A; Barlier A; Morange I; Pacak K; Taïeb D Clin Endocrinol (Oxf); 2013 Aug; 79(2):170-7. PubMed ID: 23230826 [TBL] [Abstract][Full Text] [Related]
13. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers. Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114 [TBL] [Abstract][Full Text] [Related]
14. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685 [TBL] [Abstract][Full Text] [Related]
15. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000 [TBL] [Abstract][Full Text] [Related]
16. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127). Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318 [TBL] [Abstract][Full Text] [Related]
17. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178 [TBL] [Abstract][Full Text] [Related]